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 Systemic  lupus erythematosus (SLE) is a 
devastating disease that a ects mostly 
women in their childbearing years. Short- 
and medium-term survival of patients 
with SLE has greatly improved recently, 
but long-term prognosis remains poor. 
  is stresses the need to identify markers 
of SLE progression to nephritis, such as 
vascular endothelial growth factor 
(VEGF). Understanding the complex 
regulation of VEGF metabolism in 
patients with SLE could provide 
 physicians with invaluable information 
for the treatment or prevention of lupus 
nephritis. 
 SLE is an autoimmune disease charac-
terized by antibodies directed against 
various nuclear autoantigens, particu-
larly components of chromatin, such as 
double-stranded DNA, histones, nucleo-
somes, and ribonucleoproteins. 1 Nephri-
tis is one of the main causes of morbidity 
and mortality in SLE.  Important features 
of lupus nephritis include the deposition 
of auto antibodies within the glomerular 
and tubular basement membranes, and 
a local inflammatory reaction that 
includes immune complex vasculitis 
with endothelial cell damage. 2 Ulti-
mately, this leads to proteinuria and a 
decline in renal function in association 
with glomerular sclerosis and tubu-
lointerstitial . brosis. Elution of anti-
DNA antibodies from lupus kidneys and 
the correlation between increased anti-
body levels and renal / ares, as well as 
the pathogenic role of these antibodies 
in experimental murine models, show 
that autoimmune anti-DNA antibodies 
play a crucial role in injury to both the 
glomerular and the tubular compart-
ments. 3 Glomerular damage has been 
linked to proteinuria, indicating its 
importance in the pathogenesis of lupus 
nephritis.  e tubular compartment also 
plays an important role, as tubular atro-
phy and interstitial . brosis are predic-
tors of poor renal outcome in lupus 
patients. 4 Events subsequent to deposi-
tion of injurious immune complexes 
leading to renal injury have not been 
well understood but could involve 
locally produced mediators such as 
VEGF. 
 The role of VEGF in the patho genesis 
of lupus nephritis has not been eluci-
dated. Although both the serum level 
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 In kidneys from patients with lupus nephritis, Avihingsanon  et al. report 
that decreased renal expression of vascular endothelial growth factor 
(VEGF) may be a protective mechanism against renal damage and a 
predictive factor for loss of kidney function. This finding could be an 
important tool for understanding the role of VEGF in renal disease and 
for the early detection of lupus nephritis, as the long-term prognosis still 
remains poor despite improvement in medium-term survival of 
patients. 
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of VEGF and the titer of anti-DNA 
antibodies are elevated in patients with 
lupus, they do not correlate. VEGF 
could play a protective role in the pres-
ervation of organ function, probably 
through maintenance of endothelial-
cell function and integrity of vascula-
ture. 
 Avihingsanon  et al. 5 (this issue) show 
that VEGF expression is lower in lupus 
kidneys and that renal VEGF content is 
negatively correlated with glomerular 
endocapillary proliferation, crescent 
 formation, and high histological activity 
index.  is . nding is of particular inter-
est because both serum and urine levels 
of VEGF are signi. cantly increased in 
patients with lupus nephritis. Lower syn-
thesis of VEGF in lupus kidneys is likely 
a consequence of the initial kidney injury, 
due to circulating autoantibodies. As the 
serum level of VEGF is increased in lupus 
patients, and VEGF is considered a pro-
tective factor, this raises an important 
question. 
 Why isn ’ t VEGF protecting the 
kidney in patients with lupus? 
 An increased serum level of VEGF 
 implies that glomerular endothelial cells 
are presented with amounts of VEGF 
that should be su6  cient to  ensure their 
integrity. However, lupus nephritis is 
 associated with signi. cant endothe-
lial cell injury. 2 A possible  explanation 
is that, in addition to VEGF, the se-
rum level of the soluble form of VEGF 
 receptor-1 (sFlt1) is also signi. cantly 
increased in patients with lupus nephri-
tis. 6 Because this receptor, in both its 
membrane form (Flt1) and its soluble 
form (sFlt1), has a tenfold higher af-
. nity for VEGF than VEGF receptor-
2 / Flk1, 6 such an increase in serum sFlt1 
could e ectively bind circulating VEGF. 
As a consequence, less VEGF would be 
available to the glomerular endothelial 
cells, and this could explain endothe-
lial cell injury and apoptosis observed 
in patients with lupus nephritis. Altera-
tion of VEGF signaling in glomerular 
endothelial cells could also favor the 
 expression of adhesion molecules, such 
as E-selectin, vascular cell adhesion 
see original article on page 1340
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 tubule epithelial cells through two cell-
surface molecules, one with a mole-
cular weight of 100 – 120  kDa, and the 
other of 36  kDa. 1 Although these mole-
cules have not been identi. ed in these 
studies, one possible candidate is hevin, 
a protein of 664 amino acids that has 
a molecular weight of about 120  kDa. 
Binding of anti-DNA antibodies to 
 hevin on the surface of lymphocytes 
triggers the internalization and nuclear 
 localization of the antibodies. Binding 
of anti-DNA antibodies from lupus pa-
tients to proximal tubule epithelial cells 
leads to rapid internalization and trig-
gers an in/ ammatory response charac-
terized by increased synthesis of inter-
leukin-6 and tumor necrosis  factor-  . 10 
It is  tempting to speculate that this 
 in/ ammatory response in proximal 
 tubule  epithelial cells is accompanied by 
decreased VEGF synthesis.   -Actinin 
is another membrane protein that is 
bound by anti-DNA  antibodies. Within 
the kidney,   - actinin is predominantly 
localized in the podocyte foot processes 
and mesangial cells, and anti-DNA anti-
bodies puri. ed from patients with  lupus 
nephritis bind strongly to   -actinin. 
Whether this leads to internalization of 
antibodies and in/ ammatory response, 
and therefore to decreased synthesis of 
VEGF, remains to be determined. 
 Decreased renal VEGF as a progression 
factor of kidney injury? 
 Decreased expression of VEGF in kid-
neys from patients with established 
diabetic nephropathy has recently been 
reported. 11 Low renal VEGF was cor-
related with peritubular capillary rar-
efaction, . brosis, and proteinuria.   is 
suggests that reduction in renal VEGF 
could contribute to endothelial cell in-
jury, causing capillary rarefaction, and 
leading to tubular atrophy, interstitial 
. brosis, and ultimately proteinuria. A 
similar mechanism could play a role in 
the development of lupus nephritis. 
 The discovery that decreased renal 
VEGF may be a predictive factor for 
short-term loss of kidney function in 
lupus patients could be an important tool 
to allow treatment of renal / are before 
kidney damage is too severe; however, 
since renal biopsy is usually done a? er 
molecule-1, and intercellular adhesion 
molecule-1,  observed in lupus patients. 
Because damage to glomerular endothe-
lial cells causes increased exposure of 
the glomerular basement membrane to 
the circulation, and circulating DNA can 
bind directly to it, 7 this could permit cir-
culating autoantibodies to bind glomer-
ular basement membrane-bound DNA. 
  is deposition of immune complexes 
on the glomerular basement mem-
brane could in turn attract monocytes, 
which would bind the endothelial cells 
expressing these adhesion molecules. 
  is could explain the development of 
vasculitis in spite of a high level of cir-
culating VEGF. Activated macrophages 
in the kidney produce proin/ ammatory 
cytokines, which induce a chronic in-
/ ammatory response that would culmi-
nate in extracellular matrix expansion in 
the  glomeruli and the tubulointerstitial 
space, and proteinuria ( Figure 1 ). 
 What is the mechanism of decreased 
VEGF synthesis in lupus kidneys? 
  e main site of VEGF production in 
the kidney has long been thought to be 
the podocytes; 8 however, recent stud-
ies 5,9 have shown substantial produc-
tion of VEGF in the proximal tubule 
epithelial cells. Avihingsanon  et al. 5 
show that  expression of renal VEGF 
decreases in both podocytes and proxi-
mal tubule epithelial cells. One pos-
sible explanation could be the passage 
of  autoimmune antibodies through the 
leaky glomerular basement membrane 
into the urine.   is allows immune 
complexes to be in direct contact with 
both podocytes and proximal tubule 
epithelial cells. Anti-DNA antibodies 
can directly interact with non-DNA 
antigens present on the surface of sev-
eral cell types, such as laminin, heparan 
sulfate, and collagen type IV. 1 In addi-
tion, these antibodies can bind  proximal 
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 Figure 1  |  Increased circulating VEGF decreases renal VEGF in lupus nephritis. An 
increased level of sFlt1 in lupus patients prevents circulating VEGF from binding to Flk1 on 
glomerular endothelial cells (GEndos ), leading to endothelial-cell injury and increased expo-
sure of the glomerular basement membrane (GBM) to autoantibodies. This would also lead to 
passage of autoantibodies in the urinary space, that could then injure podocytes and proximal 
tubular epithelial cells (PTECs), the two main sources of VEGF in the kidney. dsDNA, double-
stranded DNA. 
 commentar y 
Kidney International (2009) 75    1253
clinical indices of renal injury are mani-
fest, one has to look for other VEGF 
parameters. As it is possible that the 
serum level of VEGF increases before the 
renal content of VEGF decreases, this 
could allow precise timing of interven-
tion. It is important to test this hypoth-
esis in the clinical setting. Understanding 
the complex regulation of VEGF meta-
bolism in lupus patients could provide 
physicians with invaluable information 
for the treatment or prevention of lupus 
nephritis. 
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 Arachidonic acid (AA) has long been 
found to be metabolized by cyclooxy-
genase and lipoxygenase enzymes to 
prostaglandins, prostacyclin, throm-
boxane, leukotrienes, and 5-, 12-, 
and 15-hydroxyeicosatetraenoic acid 
(HETE). Recently, it was found that AA 
is also metabolized by the   -hydroxy-
lase cytochrome P450 (CYP) enzymes to 
form epoxyeicosatrienoic acids, dihy-
droxyeicosatetraenoic acids, 19-HETE, 
20-HETE, and other forms of HETE. 
The metabolites of AA generated by the 
P450 enzymes have been found to play 
important roles in the regulation of vas-
cular tone in renal, cerebral, coronary, 
and skeletal muscle arterioles and in 
pulmonary circulation. 1,2 More than 
500  CYP genes have been identified; 
among them,  CYP4F2 ,  CYP4A11 , and 
 CYP4F3B are thought to be the major 
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genes involved in metabolizing AA to 
form 20-HETE. 1,2 20-HETE is a potent 
constrictor of small arteries and arteri-
oles; however, in the kidney, 20-HETE 
also regulates tubular sodium reabsorp-
tion in the proximal tubule, as well as 
in the thick ascending limb of Henle ’ s 
loop via inhibition of Na   +   -K   +   -ATPase 
activities or Na   +   -K   +   -2Cl  –  cotransport. 
Therefore, the influence of 20-HETE 
on blood pressure remains difficult to 
 predict: it could play either a prohyper-
tensive or an antihypertensive role, 
depending on its action as a vasocon-
strictor or a sodium reabsorption 
inhibitor in renal tubules. 1,3 In addi-
tion, studies in human and animal 
models also suggest diverse effects of 
 CYP gene function on blood pressure. 
In humans,  functional polymorphism 
analysis demonstrated that diverse con-
sequences resulted from genetic poly-
morphism:  the  CYP4F2  GA /  AA 
genotype was significantly associated 
with an increase in both 20-HETE 
excretion and systolic blood pressure, 
whereas the  CYP4A11 CC / TC genotype 
was significantly associated with a 
reduction in 20-HETE excretion but 
 Arachidonic acid cytochrome 
P450 4F2 in hypertension: 
what can we learn from 
a transgenic mouse model? 
 Yiqiang  Cai 1 
 The cytochrome P450-derived 20-hydroxyeicosatetraenoic acid (20-HETE) 
has known function that plays opposite roles in blood pressure: 
prohypertensive and antihypertensive. Liu  et al. report that the  CYP4F2 
transgene, driven under an exogenous promoter, increases 20-HETE 
production and is associated with increased blood pressure  in vivo . 
This study provides evidence for the first time that overexpression of 
P450 4F2 enzyme results in higher production of 20-HETE, which 
promotes hypertension. The significance of this transgenic mouse model 
is further discussed. 
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